Selection of influenza vaccine strains and developing pandemic vaccines

Vaccine

Volumn 20, Issue SUPPL. 5, 2002, Pages

  Wood, J M ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Epidemiological progression; Influenza vaccine strains; Pandemic vaccines

Indexed keywords

INFLUENZA VACCINE;

ANTIGENICITY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; EGG; EPIDEMIC; GENETIC ANALYSIS; HEN; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; VIRUS ATTENUATION; VIRUS DETECTION; VIRUS STRAIN; VIRUS VIRULENCE; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL; GENETICS; HEALTH; HEALTH SURVEY; IMMUNOLOGY; PRACTICE GUIDELINE; VACCINATION; VIROLOGY;

CLINICAL TRIALS; DISEASE OUTBREAKS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; POPULATION SURVEILLANCE; PRACTICE GUIDELINES; VACCINATION; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 0037146945     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00509-1     Document Type: Short Survey

References (13)

1. Payne A.M. The influenza programme of WHO. Bull. WHO. 8:1953;755-774.
2. WHO. Recommended composition of influenza virus vaccines for use in the 2002-2003 season. Wkly Epid Rec 2002;77:57-68.
3. Rota P., Wallis T., Harmon M.et al. Co circulation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 175:1990;59-68.
4. Potter CW. Chronicle of influenza pandemics. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Scientific Publications; 1998. p. 3-18.
5. Top F.H., Russell P.K. Swine influenza A at Fort Dix, New Jersey (January-February 1967) IV summary and speculation. J. Infect. Dis. 136:1977;5376-5380.
6. Nakajima K., Desselberger U., Palese P. Recent human influenza A (H1N1) viruses are closely related genetically to strains isolated in 1950. Nature (London). 274:1978;334-339.
7. La Montagne J.R., Noble G.R., Quinnan G.V.et al. Summary of clinical trials of inactivated influenza vaccine - 1978. Rev. Infect Dis. 5:1983;723-736.
8. Nicholson K.G., Tyrrell D.A.J., Harrison P.et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J. Biol. Stand. 7:1979;123-136.
9. Potter C.W., Clark A., Jennings E.et al. Reactogenicity and immunogenicity of inactivated influenza A (H1N1) virus vaccine in unprimed chicken: report to the Medical Research Council committee on influenza and other respiratory virus vaccines. J. Biol. Stand. 8:1980;35-48.
10. CPMP. Note for guidance on harmonisation of requirements for influenza vaccines. CPMP.BWP/214/96. Circular no. 96-0666. p. 1-22 [ http://www.emea.eu.int/pdfs/human/bwp/021496en.pdf ].
11. Treanor J.J., Wilkinson B.E., Masseoud F.et al. Safety and immunogenicity of a recombinant haemagglutinin vaccine for H5 influenza in humans. Vaccine. 19:2001;1732-1737.
12. Takada A., Kuboki N., Okazaki K.et al. Avirulent avian influenza virus as a vaccine strain against a potential human pandemic. J. Virol. 73:1999;8303-8307.
13. Nicholson K.G., Colegate A.E., Podda A.et al. Confronting a potential H5N1 pandemic: a randomised controlled trial of conventional and MF59 adjuvanted influenza A/Duck/Singapore/97 (H5N3) surface antigen vaccine. Lancet. 357:2001;1937-1943.